

Attorney's Docket No. 33339/176332



7/17/653
Herry
Jan. 13, 02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 04 2002
TECH CENTER 1600/2900

In re: Guy Serre, et al.
Appl No.: 09/254,032
Filed: April 26, 1999
For: ANTIGENS DERIVED FROM FILAGGRIN
AND THEIR USE FOR DIAGNOSING
RHEUMATOID POLYARTHRITIS"

Confirmation No.:
Group Art Unit: 1653
Examiner: H. Robinson

October 29, 2001

Commissioner for Patents
Washington, DC 20231

ELECTION WITH TRAVERSE

In response to the requirement for restriction mailed October 2, 2001, applicant provisionally elects the claims of Group I, namely Claims 1-6 drawn to an artificial antigen and an in vitro diagnosis process.

Applicant respectfully traverses the requirement for restriction, and requests reconsideration by the Examiner. The present application is the U.S. National Stage of a PCT Application. It appears that the Examiner has applied the United States standards, rather than the PCT Unity of Invention Standards. The common technical feature which is shared by all of the claims is the artificial antigen of Claims 1-4. This same technical feature is present in Claims 7-10. Thus, it clearly appears that the claims of Group I and Group II form a single general inventive concept and that the requirement of Unity of Invention, as defined in PCT Rule 13.1 is fulfilled.

Accordingly, reconsideration by the Examiner, withdrawal of the requirement for restriction, and an action on the merits of the claims as presented are earnestly solicited.


Respectfully submitted,



Raymond O. Linker, Jr.
Registration No. 26,419

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000
Fax Charlotte Office (704) 444-1111

I hereby certify that this correspondence is being:

| MAILING | FACSIMILE |
|---|--|
| <p><input checked="" type="checkbox"/> deposited with the United States Postal service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on October 29, 2001.</p> <p> Lorna Morehead</p> | <p><input type="checkbox"/> facsimile transmitted to the Patent and Trademark Office at _____, on October 29, 2001.</p> <p>_____ Signature</p> |